LL-37 vs Tesamorelin
Updated July 23, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of LL-37 and Tesamorelin (also searched as Tesamorelin vs LL-37) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
LL-37 centers on healing, while Tesamorelin leans toward metabolic. On indexed research, LL-37 is ahead (LL-37: 5 studies, Human evidence; Tesamorelin: 5, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •LL-37 is strongest for healing; Tesamorelin for metabolic.
- •Evidence: LL-37 Human evidence (5 studies) vs Tesamorelin Human clinical (5).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Human Cathelicidin | Antimicrobial Peptide
GHRH Analog | Visceral Fat Reduction
LL-37 vs Tesamorelin: side-by-side
| Metric | LL-37 | Tesamorelin |
|---|---|---|
| Class | Immune | GH |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 5 | 5 |
| Research level | Well Studied | FDA Approved |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 5.0▲ | 1.0 |
| Muscle & body comp | 0.0 | 2.0▲ |
| Metabolic & appetite | 0.0 | 4.0▲ |
| Neuro & mood | 0.0 | 1.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 4.0▲ | 1.0 |
| Skin & aesthetics | 0.0 | 3.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | LL-37 | Tesamorelin |
|---|---|---|
| Mechanism | — | GHRH analog |
| Route | — | Subcutaneous injection |
| Half-life | — | ~26–38 min |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is LL-37?
### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →What is Tesamorelin?
### Tesamorelin Summary Tesamorelin is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog, primarily investigated for its potential to reduce visceral fat in individuals with HIV-associated lipodystrophy. Its role in metabolic health and body composition continues to be explored in various clinical contexts.
Full Tesamorelin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 5.0/5 effect signal |
| Muscle | Tesamorelin | 2.0/5 effect signal |
| Metabolic | Tesamorelin | 4.0/5 effect signal |
| Neuro | Tesamorelin | 1.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | Tesamorelin | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack LL-37 and Tesamorelin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
LL-37 vs Tesamorelin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
LL-37 has 5 approved studies indexed (Human evidence), and Tesamorelin has 5 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is LL-37 or Tesamorelin better?
It depends on your goal. LL-37 is strongest for healing; Tesamorelin for metabolic. LL-37 has more indexed studies (5). See the goal-by-goal breakdown above.
Is LL-37 or Tesamorelin better for weight loss?
Tesamorelin shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is LL-37 or Tesamorelin better for muscle?
Tesamorelin leads on the muscle & body-composition axis (2.0/5).
Which has more research, LL-37 or Tesamorelin?
LL-37 has 5 approved studies indexed (Human evidence); Tesamorelin has 5 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack LL-37 and Tesamorelin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of LL-37 vs Tesamorelin?
LL-37: no community-reported effects logged yet. Tesamorelin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is LL-37 or Tesamorelin FDA-approved?
LL-37 is a research-use compound and is not FDA-approved. Tesamorelin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Tesamorelin better than LL-37?
For metabolic, Tesamorelin has the edge; for healing, LL-37 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 23, 2026.